Login
Sign Up
Login
Sign Up
Features
Pricing
Reg.News
Contact
Login
Sign Up
Search
Providers
Companies
⨯
LIVE
Event in Progress:
Join Here
×
Search
Providers
Companies
⨯
Features
Pricing
Event Hub
Reg.News
Short Interest
Contact
All the news articles and press releases in one place.
UK Reg. News
German Reg. News
Search
Key Announcements
Results / Trading Updates
Get free RNS email alerts for@Model.CurrentFilterValue
Currently filtered for Faron Pharmaceuticals Oy
Clear Filter
Sector
Automobile Industry
Banks
Basic Materials
Building & Construction
Chemicals
Consumer Discretionary Goods
Consumer Discretionary Services
Consumer Staple Goods
Consumer Staple Services
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Finance
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Trusts, ETFs & Funds
Utilities
Market Cap
Below £20m
£20m - £100m
£100m - £300m
£300m - £1bn
£1bn - £10bn
Over £10bn
Filters »
All
UK100
UK250
UK SmallCap
UK Other
Show:
10
25
50
100
«
1
2
3
4
»
Date / Time
Source
Ticker
Company
Sector
Market Cap
Announcement
30May22 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Presentation of Biomarker Analysis at ASCO
16May22 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - FDA and FIMEA approve BEXMAB study to begin
12May22 15:50
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Ex Vivo Data Presented at EHA2022 Congress
09May22 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Mol Cancer Ther Publishes Bexmarilimab Research
04May22 11:15
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Grant of options
22Apr22 13:01
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Board Changes
22Apr22 13:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Results of AGM
21Apr22 16:30
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Faron Presents Melanoma Data at EADO
08Apr22 15:45
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Managers’ Transactions
05Apr22 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Faron Closes HIBISCUS Trial
25Mar22 09:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Notice of Faron Pharmaceuticals Ltd’s AGM
25Mar22 07:15
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Faron´s Annual Report 2021 Published
25Mar22 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Financial Statement January 1 to December 31 2021
14Mar22 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Faron Publishes Research From INTEREST Trial
09Mar22 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Presentation of Biomarker Data at AACR 2022
07Mar22 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Notice of 2021 Full-Year Results and Annual Report
04Mar22 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Faron presents at upcoming conferences
28Feb22 17:45
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Faron Board Issues Warrants to IPF Partners
28Feb22 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Faron Obtains Debt Funding from IPF Partners
23Feb22 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Faron Updates on Bexmarilimab Development Program
14Feb22 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Faron Announces R&D Day
03Feb22 10:40
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Scientific Reports Publishes INFORAAA Results
31Jan22 13:30
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Holdings in Company
31Jan22 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Juho Jalkanen Appointed Chief Operating Officer
28Jan22 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Grant of options
24Jan22 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Faron at Proactive One2One Investor Forum
17Jan22 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Faron to Present at Redeye Fight Cancer Seminar
05Jan22 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Faron to Present at H.C. Wainwright BioConnect
04Jan22 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Faron Appoints Marie-Louise Fjällskog as CMO
21Dec21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Faron’s financial calendar for 2022
09Dec21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Faron Announces Topline MATINS Biomarker Analysis
01Dec21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Change in Faron’s Management Team
16Nov21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Faron to Present at Jefferies Conference 2021
09Nov21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Faron awarded EUR 3.8 Million in Arbitration Case
03Nov21 15:55
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Cellular and Molecular Life Sciences Publication
07Oct21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Exercise of options
05Oct21 11:30
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Holding(s) in Company
01Oct21 14:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Registration of Placing Shares with Trade Register
01Oct21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Results of Placing and Issue Price
30Sep21 16:31
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Proposed Issue and Placing of Shares
17Sep21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Presentation of Updated MATINS Data at ESMO
09Sep21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Faron Announces Presentation at ESMO Congress
07Sep21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Faron to Present at H.C. Wainwright Conference
26Aug21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Half-Year Financials, January 1 – June 30 2021
25Aug21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - First Patient Dosed in Phase II/III COVID-19 Trial
28Jul21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Notice of Half-Year Report
12Jul21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Faron to Host KOL Webinar on Clever-1 Receptor
22Jun21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Updated corporate presentation
14Jun21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Bexmarilimab granted key US patent
03Jun21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Bexmarilimab results published in CCR
17May21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - Bexmarilimab shows promising anti-tumour activity
14May21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron Pharma. Oy - US rights to patent related to Traumakine
10May21 14:30
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Holding(s) in Company
29Apr21 12:45
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Grant of options
23Apr21 13:45
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Result of AGM
23Apr21 13:45
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Board Change
29Mar21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Appointment of a Broker
25Mar21 07:45
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Exercise of Options
25Mar21 07:30
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Notice of Faron Pharmaceuticals Ltd’s AGM
25Mar21 07:15
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron´s Annual Report 2020 published
25Mar21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Financial statement January 1 to December 31 2020
22Mar21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Bexmarilimab (Clevegen) development update
11Mar21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron to Present at Oppenheimer Conference
02Mar21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron to Present at H.C. Wainwright Conference
25Feb21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Notice of Full-Year Results and Annual Report
17Feb21 16:30
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Holding(s) in Company
12Feb21 15:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Registration of Placing Shares
12Feb21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Results of Placing and Issue Price
11Feb21 16:30
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Proposed Issue and Placing of Shares
26Jan21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Update on TRAUMAKINE development
20Jan21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Bexmarilimab (Clevegen) development update
18Jan21 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
US Department of Defense to support TRAUMAKINE
04Jan21 07:00
RNS-R
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron to Present at H.C. Wainwright
21Dec20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron’s financial calendar for 2021
10Dec20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Presents at ESMO Immuno-Oncology Virtual Congress
23Nov20 07:30
RNS-R
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
To Participate in Upcoming Investor Conferences
23Nov20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Bexmarilimab (Clevegen) development update
20Nov20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Issue of Equity
16Oct20 11:35
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
First Results from WHO Solidarity Trial
14Oct20 14:15
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Grant of options
30Sep20 09:45
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Holding(s) in Company
24Sep20 07:15
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Exercise of options
24Sep20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Half-year Report
18Sep20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
MATINS trial data presented at ESMO
09Sep20 12:00
RNS-R
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron to Present at H.C. Wainwright Conference
27Aug20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Notice of Half-Year Report
18Aug20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Traumakine Update
27Jul20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Change of Adviser
08Jul20 15:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Managers’ transactions
16Jun20 07:01
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron hosts virtual R&D Day today
16Jun20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron update on pipeline progress ahead of R&D Day
15Jun20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron receives EUR 2.1 million funding from BF
11Jun20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron selected for EUR2.5 million grant from EIC
01Jun20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
MATINS Update
28May20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron announces R&D Day to be held in June
20May20 07:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Publication in Intensive Care Medicine
18May20 16:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Results of the Annual General Meeting
13May20 13:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Exercise of options
12May20 18:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Managers’ transactions
11May20 10:00
RNS
FARN:LON
Faron Pharmaceuticals Oy
Health
£84.6m
Faron receives grant from Business Finland
«
1
2
3
4
»
Date / Time
Source
Company
% Chg
30May22 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Presentation of Biomarker Analysis at ASCO
16May22 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - FDA and FIMEA approve BEXMAB study to begin
12May22 15:50
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Ex Vivo Data Presented at EHA2022 Congress
09May22 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Mol Cancer Ther Publishes Bexmarilimab Research
04May22 11:15
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Grant of options
22Apr22 13:01
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Board Changes
22Apr22 13:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Results of AGM
21Apr22 16:30
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron Presents Melanoma Data at EADO
08Apr22 15:45
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Managers’ Transactions
05Apr22 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron Closes HIBISCUS Trial
25Mar22 09:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Notice of Faron Pharmaceuticals Ltd’s AGM
25Mar22 07:15
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron´s Annual Report 2021 Published
25Mar22 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Financial Statement January 1 to December 31 2021
14Mar22 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron Publishes Research From INTEREST Trial
09Mar22 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Presentation of Biomarker Data at AACR 2022
07Mar22 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Notice of 2021 Full-Year Results and Annual Report
04Mar22 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron presents at upcoming conferences
28Feb22 17:45
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron Board Issues Warrants to IPF Partners
28Feb22 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron Obtains Debt Funding from IPF Partners
23Feb22 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron Updates on Bexmarilimab Development Program
14Feb22 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron Announces R&D Day
03Feb22 10:40
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Scientific Reports Publishes INFORAAA Results
31Jan22 13:30
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Holdings in Company
31Jan22 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Juho Jalkanen Appointed Chief Operating Officer
28Jan22 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Grant of options
24Jan22 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron at Proactive One2One Investor Forum
17Jan22 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron to Present at Redeye Fight Cancer Seminar
05Jan22 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron to Present at H.C. Wainwright BioConnect
04Jan22 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron Appoints Marie-Louise Fjällskog as CMO
21Dec21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron’s financial calendar for 2022
09Dec21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron Announces Topline MATINS Biomarker Analysis
01Dec21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Change in Faron’s Management Team
16Nov21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron to Present at Jefferies Conference 2021
09Nov21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron awarded EUR 3.8 Million in Arbitration Case
03Nov21 15:55
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Cellular and Molecular Life Sciences Publication
07Oct21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Exercise of options
05Oct21 11:30
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Holding(s) in Company
01Oct21 14:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Registration of Placing Shares with Trade Register
01Oct21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Results of Placing and Issue Price
30Sep21 16:31
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Proposed Issue and Placing of Shares
17Sep21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Presentation of Updated MATINS Data at ESMO
09Sep21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron Announces Presentation at ESMO Congress
07Sep21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron to Present at H.C. Wainwright Conference
26Aug21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Half-Year Financials, January 1 – June 30 2021
25Aug21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - First Patient Dosed in Phase II/III COVID-19 Trial
28Jul21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Notice of Half-Year Report
12Jul21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron to Host KOL Webinar on Clever-1 Receptor
22Jun21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Updated corporate presentation
14Jun21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Bexmarilimab granted key US patent
03Jun21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Bexmarilimab results published in CCR
17May21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Bexmarilimab shows promising anti-tumour activity
14May21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - US rights to patent related to Traumakine
10May21 14:30
RNS
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
29Apr21 12:45
RNS
Faron Pharmaceuticals Oy
-0.42%
Grant of options
23Apr21 13:45
RNS
Faron Pharmaceuticals Oy
-0.42%
Result of AGM
23Apr21 13:45
RNS
Faron Pharmaceuticals Oy
-0.42%
Board Change
29Mar21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Appointment of a Broker
25Mar21 07:45
RNS
Faron Pharmaceuticals Oy
-0.42%
Exercise of Options
25Mar21 07:30
RNS
Faron Pharmaceuticals Oy
-0.42%
Notice of Faron Pharmaceuticals Ltd’s AGM
25Mar21 07:15
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron´s Annual Report 2020 published
25Mar21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Financial statement January 1 to December 31 2020
22Mar21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Bexmarilimab (Clevegen) development update
11Mar21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron to Present at Oppenheimer Conference
02Mar21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron to Present at H.C. Wainwright Conference
25Feb21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Notice of Full-Year Results and Annual Report
17Feb21 16:30
RNS
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
12Feb21 15:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Registration of Placing Shares
12Feb21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Results of Placing and Issue Price
11Feb21 16:30
RNS
Faron Pharmaceuticals Oy
-0.42%
Proposed Issue and Placing of Shares
26Jan21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Update on TRAUMAKINE development
20Jan21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Bexmarilimab (Clevegen) development update
18Jan21 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
US Department of Defense to support TRAUMAKINE
04Jan21 07:00
RNS-R
Faron Pharmaceuticals Oy
-0.42%
Faron to Present at H.C. Wainwright
21Dec20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron’s financial calendar for 2021
10Dec20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Presents at ESMO Immuno-Oncology Virtual Congress
23Nov20 07:30
RNS-R
Faron Pharmaceuticals Oy
-0.42%
To Participate in Upcoming Investor Conferences
23Nov20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Bexmarilimab (Clevegen) development update
20Nov20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Issue of Equity
16Oct20 11:35
RNS
Faron Pharmaceuticals Oy
-0.42%
First Results from WHO Solidarity Trial
14Oct20 14:15
RNS
Faron Pharmaceuticals Oy
-0.42%
Grant of options
30Sep20 09:45
RNS
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
24Sep20 07:15
RNS
Faron Pharmaceuticals Oy
-0.42%
Exercise of options
24Sep20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Half-year Report
18Sep20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
MATINS trial data presented at ESMO
09Sep20 12:00
RNS-R
Faron Pharmaceuticals Oy
-0.42%
Faron to Present at H.C. Wainwright Conference
27Aug20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Notice of Half-Year Report
18Aug20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Traumakine Update
27Jul20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Change of Adviser
08Jul20 15:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Managers’ transactions
16Jun20 07:01
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron hosts virtual R&D Day today
16Jun20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron update on pipeline progress ahead of R&D Day
15Jun20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron receives EUR 2.1 million funding from BF
11Jun20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron selected for EUR2.5 million grant from EIC
01Jun20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
MATINS Update
28May20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron announces R&D Day to be held in June
20May20 07:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Publication in Intensive Care Medicine
18May20 16:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Results of the Annual General Meeting
13May20 13:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Exercise of options
12May20 18:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Managers’ transactions
11May20 10:00
RNS
Faron Pharmaceuticals Oy
-0.42%
Faron receives grant from Business Finland
«
1
2
3
4
»
Date / Time
Company
% Chg
30May22 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Presentation of Biomarker Analysis at ASCO
16May22 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - FDA and FIMEA approve BEXMAB study to begin
12May22 15:50
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Ex Vivo Data Presented at EHA2022 Congress
09May22 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Mol Cancer Ther Publishes Bexmarilimab Research
04May22 11:15
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Grant of options
22Apr22 13:01
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Board Changes
22Apr22 13:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Results of AGM
21Apr22 16:30
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron Presents Melanoma Data at EADO
08Apr22 15:45
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Managers’ Transactions
05Apr22 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron Closes HIBISCUS Trial
25Mar22 09:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Notice of Faron Pharmaceuticals Ltd’s AGM
25Mar22 07:15
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron´s Annual Report 2021 Published
25Mar22 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Financial Statement January 1 to December 31 2021
14Mar22 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron Publishes Research From INTEREST Trial
09Mar22 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Presentation of Biomarker Data at AACR 2022
07Mar22 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Notice of 2021 Full-Year Results and Annual Report
04Mar22 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron presents at upcoming conferences
28Feb22 17:45
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron Board Issues Warrants to IPF Partners
28Feb22 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron Obtains Debt Funding from IPF Partners
23Feb22 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron Updates on Bexmarilimab Development Program
14Feb22 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron Announces R&D Day
03Feb22 10:40
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Scientific Reports Publishes INFORAAA Results
31Jan22 13:30
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Holdings in Company
31Jan22 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Juho Jalkanen Appointed Chief Operating Officer
28Jan22 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Grant of options
24Jan22 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron at Proactive One2One Investor Forum
17Jan22 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron to Present at Redeye Fight Cancer Seminar
05Jan22 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron to Present at H.C. Wainwright BioConnect
04Jan22 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron Appoints Marie-Louise Fjällskog as CMO
21Dec21 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron’s financial calendar for 2022
09Dec21 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron Announces Topline MATINS Biomarker Analysis
01Dec21 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Change in Faron’s Management Team
16Nov21 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron to Present at Jefferies Conference 2021
09Nov21 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron awarded EUR 3.8 Million in Arbitration Case
03Nov21 15:55
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Cellular and Molecular Life Sciences Publication
07Oct21 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Exercise of options
05Oct21 11:30
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Holding(s) in Company
01Oct21 14:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Registration of Placing Shares with Trade Register
01Oct21 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Results of Placing and Issue Price
30Sep21 16:31
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Proposed Issue and Placing of Shares
17Sep21 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Presentation of Updated MATINS Data at ESMO
09Sep21 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron Announces Presentation at ESMO Congress
07Sep21 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron to Present at H.C. Wainwright Conference
26Aug21 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Half-Year Financials, January 1 – June 30 2021
25Aug21 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - First Patient Dosed in Phase II/III COVID-19 Trial
28Jul21 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Notice of Half-Year Report
12Jul21 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Faron to Host KOL Webinar on Clever-1 Receptor
22Jun21 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Updated corporate presentation
14Jun21 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Bexmarilimab granted key US patent
03Jun21 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Bexmarilimab results published in CCR
17May21 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - Bexmarilimab shows promising anti-tumour activity
14May21 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron Pharma. Oy - US rights to patent related to Traumakine
10May21 14:30
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
29Apr21 12:45
Faron Pharmaceuticals Oy
-0.42%
Grant of options
23Apr21 13:45
Faron Pharmaceuticals Oy
-0.42%
Result of AGM
23Apr21 13:45
Faron Pharmaceuticals Oy
-0.42%
Board Change
29Mar21 07:00
Faron Pharmaceuticals Oy
-0.42%
Appointment of a Broker
25Mar21 07:45
Faron Pharmaceuticals Oy
-0.42%
Exercise of Options
25Mar21 07:30
Faron Pharmaceuticals Oy
-0.42%
Notice of Faron Pharmaceuticals Ltd’s AGM
25Mar21 07:15
Faron Pharmaceuticals Oy
-0.42%
Faron´s Annual Report 2020 published
25Mar21 07:00
Faron Pharmaceuticals Oy
-0.42%
Financial statement January 1 to December 31 2020
22Mar21 07:00
Faron Pharmaceuticals Oy
-0.42%
Bexmarilimab (Clevegen) development update
11Mar21 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron to Present at Oppenheimer Conference
02Mar21 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron to Present at H.C. Wainwright Conference
25Feb21 07:00
Faron Pharmaceuticals Oy
-0.42%
Notice of Full-Year Results and Annual Report
17Feb21 16:30
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
12Feb21 15:00
Faron Pharmaceuticals Oy
-0.42%
Registration of Placing Shares
12Feb21 07:00
Faron Pharmaceuticals Oy
-0.42%
Results of Placing and Issue Price
11Feb21 16:30
Faron Pharmaceuticals Oy
-0.42%
Proposed Issue and Placing of Shares
26Jan21 07:00
Faron Pharmaceuticals Oy
-0.42%
Update on TRAUMAKINE development
20Jan21 07:00
Faron Pharmaceuticals Oy
-0.42%
Bexmarilimab (Clevegen) development update
18Jan21 07:00
Faron Pharmaceuticals Oy
-0.42%
US Department of Defense to support TRAUMAKINE
04Jan21 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron to Present at H.C. Wainwright
21Dec20 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron’s financial calendar for 2021
10Dec20 07:00
Faron Pharmaceuticals Oy
-0.42%
Presents at ESMO Immuno-Oncology Virtual Congress
23Nov20 07:30
Faron Pharmaceuticals Oy
-0.42%
To Participate in Upcoming Investor Conferences
23Nov20 07:00
Faron Pharmaceuticals Oy
-0.42%
Bexmarilimab (Clevegen) development update
20Nov20 07:00
Faron Pharmaceuticals Oy
-0.42%
Issue of Equity
16Oct20 11:35
Faron Pharmaceuticals Oy
-0.42%
First Results from WHO Solidarity Trial
14Oct20 14:15
Faron Pharmaceuticals Oy
-0.42%
Grant of options
30Sep20 09:45
Faron Pharmaceuticals Oy
-0.42%
Holding(s) in Company
24Sep20 07:15
Faron Pharmaceuticals Oy
-0.42%
Exercise of options
24Sep20 07:00
Faron Pharmaceuticals Oy
-0.42%
Half-year Report
18Sep20 07:00
Faron Pharmaceuticals Oy
-0.42%
MATINS trial data presented at ESMO
09Sep20 12:00
Faron Pharmaceuticals Oy
-0.42%
Faron to Present at H.C. Wainwright Conference
27Aug20 07:00
Faron Pharmaceuticals Oy
-0.42%
Notice of Half-Year Report
18Aug20 07:00
Faron Pharmaceuticals Oy
-0.42%
Traumakine Update
27Jul20 07:00
Faron Pharmaceuticals Oy
-0.42%
Change of Adviser
08Jul20 15:00
Faron Pharmaceuticals Oy
-0.42%
Managers’ transactions
16Jun20 07:01
Faron Pharmaceuticals Oy
-0.42%
Faron hosts virtual R&D Day today
16Jun20 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron update on pipeline progress ahead of R&D Day
15Jun20 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron receives EUR 2.1 million funding from BF
11Jun20 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron selected for EUR2.5 million grant from EIC
01Jun20 07:00
Faron Pharmaceuticals Oy
-0.42%
MATINS Update
28May20 07:00
Faron Pharmaceuticals Oy
-0.42%
Faron announces R&D Day to be held in June
20May20 07:00
Faron Pharmaceuticals Oy
-0.42%
Publication in Intensive Care Medicine
18May20 16:00
Faron Pharmaceuticals Oy
-0.42%
Results of the Annual General Meeting
13May20 13:00
Faron Pharmaceuticals Oy
-0.42%
Exercise of options
12May20 18:00
Faron Pharmaceuticals Oy
-0.42%
Managers’ transactions
11May20 10:00
Faron Pharmaceuticals Oy
-0.42%
Faron receives grant from Business Finland
«
1
2
3
4
»
Strapline
Strapline
Question 1
Answer 1
Question 2
Answer 2
Question 3
Answer 3
Question 4
Answer 4
Question 5
Answer 5
Question 6
Answer 6
Question 7
Answer 7
Question 8
Answer 8
Top
Home
Features
Pricing
Event Hub
Reg.News
Short Interest Tracker
Explore Content
Regions
UK
Rest of EMEA
N America
APAC
LatAm
Exchanges
Aquis Apex
Australian Securities Exchange
Canadian Securities Exchange
Euronext Paris
London Stock Exchange (domestic)
SIX Swiss Exchange
Sectors
Automobile Industry
Banks
Building & Construction
Chemicals
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Utilities
Small / Large Cap
UK100
UK250
UK Smallcap
UK Other Main Markets
Other
Private/EIS
EIS Single Company
EIS/SEIS Funds
IHT Products
SEIS Single Company
VCT Funds
Providers
Free/Commissioned
ACF Equity Research
Actio Advisors
Align Research
Atrium Research
BlytheRay
BNP Paribas Exane - Sponsored Research
Brand Communications
BRR Media
Calvine Partners
Capital Access Group
Capital Markets Brokers
Cavendish
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Degroof Petercam
DirectorsTalk
Doceo
Edison
Equity Development
eResearch
Fidante Partners
Five Minute Pitch TV
focusIR
Fundamental Research Corp
Galliano’s Latin Notes
goetzpartners securities Limited
H2 Radnor
Hardman & Co
Holland Advisors
Hypothesis Research
Inbound Capital
Independent Investment Research
InterAxS Global
Kepler | Trust Intelligence
Liberum
London Stock Exchange
Magnitogorsk Iron and steel works
Mello Events
Mining Network
NuWays
Paul Scott
Peel Hunt
piworld.co.uk
Proactive
Progressive Equity Research
Quantum Research Group
QuotedData
RaaS - Research as a Service
Research Tree
Resolve Research
SEAL Advisors Ltd
ShareSoc
Shore Capital
Small Cap Consumer Research LLC
StockBox
Tennyson Securities
The AIC
The Life Sciences Division
Trinity Delta
Turner Pope Investments
UK Investor Group
Vox Markets
VSA Capital
WHIreland
Winterflood Securities
Yellowstone Advisory
Zeus Capital
High Net Worth Offering
Fox-Davies Capital
ACF Equity Research
Align Research
Allenby Capital
AlphaValue
Alternative Resource Capital
Arctic Securities
Arden Partners
Auctus Advisors
Baptista Research
BNP Paribas Exane - Sponsored Research
Canaccord Genuity
Cavendish
Couloir Capital
Dowgate Capital
First Berlin
First Sentinel
GSBR Research
Hannam & Partners
Hybridan
Kemeny Capital
Liberum
Longspur Clean Energy
Louis Capital
Magnitogorsk Iron and steel works
Medley Global Advisors
Northland Capital Partners
QuotedData Professional
Shard Capital
ShareSoc
Shore Capital
Singer Capital Markets
SP Angel
Stanford Capital Partners
Stifel FirstEnergy
Stockdale Securities
Tamesis Partners
Tennyson Securities
The Life Sciences Division
Turner Pope Investments
VSA Capital
WHIreland
Whitman Howard
Yellowstone Advisory
Zeus Capital
Institutional Offering
Fox-Davies Capital
ACF Equity Research
Align Research
Allenby Capital
Alternative Resource Capital
Arctic Securities
Arden Partners
Auctus Advisors
BNP Paribas Exane
BRR Media
Calvine Partners
Canaccord Genuity
Capital Access Group
Cavendish
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Degroof Petercam
DirectorsTalk
Doceo
Dowgate Capital
Edison
Equity Development
eResearch
Fidante Partners
First Berlin
First Sentinel
Five Minute Pitch TV
Fundamental Research Corp
Galliano’s Latin Notes
Goodbody
H2 Radnor
Hannam & Partners
Hardman & Co
Holland Advisors
Hybridan
Inbound Capital
Independent Investment Research
InterAxS Global
Investec Bank
Kemeny Capital
Kepler | Absolute Hedge
Kepler | Trust Intelligence
Liberum
London Stock Exchange
Longspur Clean Energy
Magnitogorsk Iron and steel works
Mello Events
Mining Network
Northland Capital Partners
Numis
NuWays
Panmure Gordon
Peel Hunt
piworld.co.uk
Proactive
Quantum Research Group
QuotedData
RaaS - Research as a Service
Research Tree
Shard Capital
ShareSoc
Shore Capital
Singer Capital Markets
Small Cap Consumer Research LLC
SP Angel
Stanford Capital Partners
Stifel
StockBox
Tamesis Partners
Tennyson Securities
The AIC
The Life Sciences Division
Trinity Delta
UK Investor Group
Velocity Trade
Vox Markets
VSA Capital
WHIreland
Winterflood Securities
Yellowstone Advisory
Zeus Capital
Contact
Sign Up
Sign In
Share: